NasdaqCM:BTAI

Stock Analysis Report

Executive Summary

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States.

Snowflake

Fundamentals

Excellent balance sheet with moderate growth potential.

Share Price & News

How has BioXcel Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.7%

NasdaqCM:BTAI

2.8%

US Biotechs

0.1%

US Market


1 Year Return

25.5%

NasdaqCM:BTAI

-5.6%

US Biotechs

1.2%

US Market

BTAI outperformed the Biotechs industry which returned -9% over the past year.

BTAI outperformed the Market in United States of America which returned 0.7% over the past year.


Share holder returns

BTAIIndustryMarket
7 Day0.7%2.8%0.1%
30 Day-0.09%1.7%0.6%
90 Day10.8%-6.0%0.9%
1 Year25.5%25.5%-4.8%-5.6%3.4%1.2%
3 Yearn/a18.6%14.4%46.5%36.7%
5 Yearn/a14.7%9.6%55.1%37.9%

Price Volatility Vs. Market

How volatile is BioXcel Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioXcel Therapeutics undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

BioXcel Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).

BioXcel Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

BioXcel Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.

BioXcel Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for BioXcel Therapeutics, we can't assess if its growth is good value.


Price Based on Value of Assets

BioXcel Therapeutics is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is BioXcel Therapeutics expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

55.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if BioXcel Therapeutics is high growth as no revenue estimate data is available.

BioXcel Therapeutics's earnings are expected to grow significantly at over 20% yearly.

Unable to compare BioXcel Therapeutics's revenue growth to the United States of America market average as no estimate data is available.

BioXcel Therapeutics's earnings growth is expected to exceed the United States of America market average.

BioXcel Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if BioXcel Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has BioXcel Therapeutics performed over the past 5 years?

-167.6%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

BioXcel Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare BioXcel Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare BioXcel Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if BioXcel Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if BioXcel Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if BioXcel Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is BioXcel Therapeutics's financial position?


Financial Position Analysis

BioXcel Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

BioXcel Therapeutics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

BioXcel Therapeutics's level of debt (2.4%) compared to net worth is satisfactory (less than 40%).

Unable to establish if BioXcel Therapeutics's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 48.6x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

BioXcel Therapeutics has sufficient cash runway for 1.9 years based on current free cash flow.

BioXcel Therapeutics has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 95.9% each year.


Next Steps

Dividend

What is BioXcel Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate BioXcel Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate BioXcel Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as BioXcel Therapeutics has not reported any payouts.

Unable to verify if BioXcel Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as BioXcel Therapeutics has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of BioXcel Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of BioXcel Therapeutics's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

Vimal Mehta (57yo)

2.1yrs

Tenure

US$701,609

Compensation

Dr. Vimal D. Mehta, Ph.D., is Co-founder of BioXcel Corporation and serves as its Chairman and Chief Executive Officer. He has been Chief Executive Officer, President and Secretary of BioXcel Therapeutics, ...


CEO Compensation Analysis

Vimal's remuneration is lower than average for companies of similar size in United States of America.

Vimal's compensation has increased whilst company is loss making.


Management Age and Tenure

1.3yrs

Average Tenure

57yo

Average Age

The average tenure for the BioXcel Therapeutics management team is less than 2 years, this suggests a new team.


Board Age and Tenure

1.3yrs

Average Tenure

56yo

Average Age

The average tenure for the BioXcel Therapeutics board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month insider trading information.


Recent Insider Transactions

BuyUS$8,76614 Dec 18
Vimal Mehta
EntityIndividual
Role
Founder
Member of the Board of Directors
Shares2,000
Max PriceUS$4.50
BuyUS$44,04507 Dec 18
Peter Mueller
EntityIndividual
Role
Chairman of the Board
Shares8,795
Max PriceUS$5.01
BuyUS$20,54406 Dec 18
Peter Mueller
EntityIndividual
Role
Chairman of the Board
Shares4,007
Max PriceUS$5.15
BuyUS$4,69206 Dec 18
Frank Yocca
EntityIndividual
Role
Chief Scientific Officer
Shares900
Max PriceUS$5.23
BuyUS$10,28504 Dec 18
Vimal Mehta
EntityIndividual
Role
Founder
Member of the Board of Directors
Shares2,000
Max PriceUS$5.20
BuyUS$2,60004 Dec 18
Richard Steinhart
EntityIndividual
Role
Chief Financial Officer
Shares500
Max PriceUS$5.20
BuyUS$5,00030 Nov 18
Richard Steinhart
EntityIndividual
Role
Chief Financial Officer
Shares1,000
Max PriceUS$5.00
BuyUS$4,85130 Nov 18
Frank Yocca
EntityIndividual
Role
Chief Scientific Officer
Shares950
Max PriceUS$5.20
BuyUS$4,91530 Nov 18
Krishnan Nandabalan
EntityIndividual
Role
Member of the Board of Directors
Shares1,000
Max PriceUS$4.92
BuyUS$5,10430 Nov 18
Vimal Mehta
EntityIndividual
Role
Founder
Member of the Board of Directors
Shares1,000
Max PriceUS$5.20
BuyUS$782,10814 Sep 18
DNCA Finance
EntityCompany
Shares94,801
Max PriceUS$8.25

Ownership Breakdown


Management Team

  • Cedric Burg

    VP and Head of Global Clinical Operations & Project Management

    • Tenure: 1.0yrs
  • Vimal Mehta (57yo)

    Founder

    • Tenure: 2.1yrs
    • Compensation: $701.61k
  • David Hanley

    Head of Global Pharmaceutical Development and Operations & VP

    • Tenure: 0.8yrs
  • Chetan Lathia

    Senior VP and Head of Translational Medicine

    • Tenure: 0.8yrs
  • Vince O'Neill (49yo)

    Senior VP & Chief Medical Officer

    • Tenure: 1.9yrs
    • Compensation: $663.30k
  • Chids Mahadevan (46yo)

    VP of Finance & Chief Accounting Officer

  • Frank Yocca (62yo)

    Chief Scientific Officer

    • Tenure: 2.0yrs
    • Compensation: $654.41k
  • Rich Steinhart (61yo)

    Chief Financial Officer

    • Tenure: 1.7yrs
    • Compensation: $447.29k
  • Robert Risinger

    Vice President of Clinical Development

    • Tenure: 0.4yrs

Board Members

  • Stephen Marder

    Member of Clinical Advisory Board

    • Tenure: 0.9yrs
  • Vimal Mehta (57yo)

    Founder

    • Tenure: 2.2yrs
    • Compensation: $701.61k
  • Nandu Nandabalan (55yo)

    Director

    • Tenure: 2.1yrs
  • Peter Mueller (61yo)

    Chairman of the Board of Directors

    • Tenure: 1.8yrs
    • Compensation: $336.71k
  • Sandeep Laumas (49yo)

    Director

    • Tenure: 1.8yrs
    • Compensation: $315.04k
  • Sheila Gujrathi (48yo)

    Member of Advisory Board

  • Steve Paul (67yo)

    Member of Advisory Board

  • George Grossberg

    Member of Clinical Advisory Board

    • Tenure: 0.9yrs
  • Alan Breier

    Member of Clinical Advisory Board

    • Tenure: 0.9yrs
  • Sheldon Preskorn

    Member of Clinical Advisory Board

    • Tenure: 0.9yrs

Company Information

BioXcel Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioXcel Therapeutics, Inc.
  • Ticker: BTAI
  • Exchange: NasdaqCM
  • Founded: 2017
  • Industry: biotechnology
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$170.601m
  • Shares outstanding: 15.67m
  • Website: Click here

Number of Employees


Location

  • BioXcel Therapeutics, Inc.
  • 555 Long Wharf Drive
  • 5th Floor
  • New Haven
  • Connecticut
  • 6511
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BTAINasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 1970
BX2DB (Deutsche Boerse AG)YesCommon StockDEEURJan 1970

Biography

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United State ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/06/18 00:54
End of Day Share Price2019/06/17 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.